Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Sherif M Hamdy, Maged Abdel-Naseer, Hatem S Shehata, Amr Hassan, Alaa Elmazny, Nevin M Shalaby, Noha T Abokrysha, Nirmeen A Kishk, Mona A F Nada, Sandra M Ahmed, Mohamed I Hegazy, Doaa Mekkawy, Husam S Mourad, Ahmed Abdelalim & Thomas Berger. (2020) Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach. Therapeutics and Clinical Risk Management 16, pages 651-662.
Read now
Read now
Aaron L Boster, Corey C Ford, Orit Neudorfer & Yossi Gilgun-Sherki. (2015) Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics 15:6, pages 575-586.
Read now
Read now
Matteo Caporro, Giulio Disanto, Claudio Gobbi & Chiara Zecca. (2014) Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment. Patient Preference and Adherence 8, pages 1123-1134.
Read now
Read now
Fabricio González-Andrade & José Luis Alcaraz-Alvarez. (2010) Disease-modifying therapies in relapsing–remitting multiple sclerosis. Neuropsychiatric Disease and Treatment 6, pages 365-373.
Read now
Read now
Articles from other publishers (11)
Daniel Chen, Ivan Wolansky, Jaime Imitola, Carl Malchoff, Rong Wu, Suhayl Dhib-Jalbut, Ketan Bulsara & Leo Wolansky. (2022) Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity. Journal of International Medical Research 50:2, pages 030006052210769.
Crossref
Crossref
Magnhild Sandberg-Wollheim, Orit Neudorfer, Augusto Grinspan, Bianca Weinstock-Guttman, Judith Haas, Guillermo Izquierdo, Claire Riley, Amy Perrin Ross, Peleg Baruch, Talya Drillman & Patricia K. Coyle. (2018) Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database. International Journal of MS Care 20:1, pages 9-14.
Crossref
Crossref
Tjalf Ziemssen, Pasquale Calabrese, Iris-Katharina Penner & Rainer Apfel. (2016) QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients. Journal of Neurology 263:4, pages 784-791.
Crossref
Crossref
Olga Zapletalová. (2016) Glatiramer acetate: long-term immunomodulatory therapy in multiple sclerosis - safety, efficacy,. Neurologie pro praxi 17:2, pages 95-99.
Crossref
Crossref
Kazumasa Yokoyama & Nobutaka Hattori. (2016) Immunomodulatory effects of glatiramer acetate as they relate to stage-specific immune dysregulation in multiple sclerosis. Folia Pharmacologica Japonica 148:2, pages 105-120.
Crossref
Crossref
Shih C. Chang, Redwan Huq, Sandeep Chhabra, Christine Beeton, Michael W. Pennington, Brian J. Smith & Raymond S. Norton. (2015)
N-terminally extended analogues of the K
+
channel toxin from
Stichodactyla helianthus
as potent and selective blockers of the voltage-gated potassium channel Kv1.3
. FEBS Journal 282:12, pages 2247-2259.
Crossref
Crossref
T. L. Vollmer, P. S. Sorensen, K. Selmaj, F. Zipp, E. Havrdova, J. A. Cohen, N. Sasson, Y. Gilgun-Sherki & D. L. Arnold. (2014) A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology 261:4, pages 773-783.
Crossref
Crossref
Lesley J. Scott. (2013) Glatiramer Acetate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis. CNS Drugs 27:11, pages 971-988.
Crossref
Crossref
Oscar Fernández. (2012) Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis. Journal of Central Nervous System Disease 4, pages JCNSD.S8755.
Crossref
Crossref
J. Rick Turner. (2011) Editor’s Commentary: Letters to the Editor, a New Publishing Partner, and Benefit-Risk Estimation. Drug Information Journal 45:5, pages 559-564.
Crossref
Crossref
Stephen Krieger. (2011) Multiple Sclerosis Therapeutic Pipeline: Opportunities and Challenges. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:2, pages 192-206.
Crossref
Crossref